Silverback Therapeutics (SBTX) to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference

Go back to Silverback Therapeutics (SBTX) to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference

Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference

April 8, 2021 8:00 AM EDT

SBT6290 Shown to Activate Myeloid Cells and Drive Anti-tumor Effects in Nectin4-expressing Solid Tumors

SEATTLE--(BUSINESS WIRE)-- Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases, will present preclinical data on its second product candidate, SBT6290, at the American Association of Cancer Research (AACR) 2021 Annual Conference, taking place virtually April 10-15. The data highlight the ability of SBT6290, a systemically administered Nectin4-directed TLR8... More